亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

High baseline prevalence of atopic comorbidities and medication use in children treated with allergy immunotherapy in the REAl-world effeCtiveness in allergy immunoTherapy (REACT) study

医学 过敏 免疫疗法 口服免疫疗法 基线(sea) 儿科 内科学 食物过敏 免疫学 癌症 海洋学 地质学
作者
Benedikt Fritszching,Celeste Michala Porsbjerg,Sarah Buchs,Julie Rask Larsen,Nick Freemantle,Marco Contoli
出处
期刊:Frontiers in Pediatrics [Frontiers Media]
卷期号:11: 1136942-1136942 被引量:7
标识
DOI:10.3389/fped.2023.1136942
摘要

Background: Respiratory allergy, commonly manifesting as allergic rhinitis (AR) and asthma, is a chronic progressive disease that frequently starts in childhood. Allergy immunotherapy (AIT) is the only causal treatment for respiratory allergy with the potential to modify the underlying cause of allergy and, ultimately, prevent disease progression. This analysis aimed to determine if AIT is received sufficiently early to halt the progression of allergic disease, by characterizing the burden and progression of disease in children prior to AIT initiation in real-life clinical practice. Methods: The REAl-world effeCtiveness in allergy immunoTherapy (REACT) study was a large retrospective cohort study using German claims data between 2007 and 2017. Characteristics of two pre-defined AIT age cohorts from the REACT study - children (aged <18 years) and adults (aged ≥18 years) - were evaluated during the 1-year period before the first AIT prescription. For comparison, a control group of all subjects with a confirmed diagnosis of AR and without prescriptions for AIT was included. Burden of disease was assessed using diagnostic codes for atopic comorbidities [e.g., atopic dermatitis (AD), asthma, and acute allergic conjunctivitis] and non-atopic comorbidities (e.g., migraine, headache); medication use, recorded as prescriptions for symptom-relieving AR medication and reliever/controller medication for asthma, was also assessed. Data were analyzed descriptively, using summary statistics. Results: = 1,003,332). In the two age-specific AIT cohorts, children consistently showed the highest prevalence of atopic comorbidities compared to adults (AIT children, AIT adults - asthma: 41.4%, 34.5%; AD: 19.9%, 10.2%; acute allergic conjunctivitis: 13.6%, 10.2%). Generally, prescriptions per year for symptom-relieving AR and asthma treatments were also higher for children initiating AIT vs. adults (AIT children, AIT adults - AR prescriptions per subject: 1.72, 0.73; asthma prescriptions per subject: 1.42, 0.79). Conclusions: Children with AR who are offered AIT in real-life show considerable disease burden prior to initiation. As AIT may alleviate the burden and halt the progression of allergic disease, considering AIT earlier in the disease course may be warranted.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
minne完成签到,获得积分10
2秒前
霸气一斩完成签到,获得积分10
4秒前
康子浩发布了新的文献求助10
8秒前
9秒前
和谐的山水完成签到,获得积分10
13秒前
orixero的应助被废纸箱采纳,获得10
16秒前
wanci的应助被笑点低的无血采纳,获得10
16秒前
17秒前
冷酷惠完成签到 ,获得积分10
30秒前
Sun1314完成签到,获得积分10
40秒前
ppp发布了新的文献求助10
41秒前
44秒前
悦耳友菱完成签到,获得积分10
47秒前
56秒前
56秒前
爱听歌的冬天完成签到,获得积分10
1分钟前
睡个好觉啦完成签到 ,获得积分10
1分钟前
1分钟前
魔幻的松思完成签到,获得积分10
1分钟前
原神大王的应助被雪山大地采纳,获得10
1分钟前
cc发布了新的文献求助10
1分钟前
NexusExplorer的应助被康子浩采纳,获得10
1分钟前
1分钟前
从容飞雪完成签到,获得积分10
1分钟前
1分钟前
1分钟前
ppp发布了新的文献求助10
1分钟前
康子浩发布了新的文献求助10
1分钟前
哇咔咔完成签到 ,获得积分10
1分钟前
桐桐的应助被barrylee采纳,获得10
1分钟前
完美世界的应助被科研通管家采纳,获得10
1分钟前
打打的应助被科研通管家采纳,获得10
1分钟前
嘻嘻哈哈的应助被科研通管家采纳,获得10
1分钟前
脑洞疼的应助被科研通管家采纳,获得10
1分钟前
丘比特的应助被科研通管家采纳,获得10
1分钟前
香蕉觅云的应助被科研通管家采纳,获得10
1分钟前
调皮怀薇的应助被科研通管家采纳,获得10
1分钟前
嘻嘻哈哈的应助被科研通管家采纳,获得10
1分钟前
科研通AI6.4的应助被cc采纳,获得10
1分钟前
自然的绮山完成签到,获得积分10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Hidden Empire of Finance: How Wall Street Profits from Our Cities and Fuels Global Inequality 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8165884
求助须知:如何正确求助?哪些是违规求助? 9559318
关于积分的说明 21749884
捐赠科研通 7756681
什么是DOI,文献DOI怎么找? 3429083
关于科研通互助平台的介绍 2553367
邀请新用户注册赠送积分活动 2473623